Lung cancer treatment and mortality for Aboriginal people in New South Wales, Australia: results from a population-based record linkage study and medical record audit
BMC Cancer volume 16, Article number: 289 (2016)
The aim of this study was to compare surgical treatment received by Aboriginal and non-Aboriginal people with non-small cell lung cancer (NSCLC) in New South Wales (NSW), Australia and to examine whether patient and disease characteristics are associated with any disparities found. An additional objective was to describe the adjuvant treatments received by Aboriginal people diagnosed with NSCLC in NSW. Finally, we compared the risk of death from NSCLC for Aboriginal and non-Aboriginal people.
We used logistic regression and competing risks regression to analyse population-based cancer registry records for people diagnosed with NSCLC in NSW, 2001–2007, linked to hospital inpatient episodes and deaths. We also analysed treatment patterns from a medical record audit for 170 Aboriginal people diagnosed with NSCLC in NSW, 2000–2010.
Of 20,154 people diagnosed with primary lung cancer, 341 (1.7 %) were Aboriginal. Larger proportions of Aboriginal people were younger, female, living outside major cities or in areas of greater socioeconomic disadvantage, smoking at the time of diagnosis and had comorbidities. Although Aboriginal people were, on average, younger at diagnosis with non-metastatic NSCLC than non-Aboriginal people, only 30.8 % of Aboriginal people received surgery, compared with 39.5 % of non-Aboriginal people. Further, Aboriginal people who were not receiving surgery, at the time of diagnosis, were more likely to be younger, live in major cities and have no comorbidities. The observed risk of death from NSCLC 5 years after diagnosis was higher for 266 Aboriginal people (83.3 % 95 % CI 77.5–87.7) than for 15,491 non-Aboriginal people (77.6 % 95 % CI 76.9–78.3) and the adjusted subhazard ratio was 1.32 (95 % CI 1.14–1.52). From the medical record audit, 29 % of Aboriginal people with NSCLC had potentially curative treatment, 45 % had palliative radiotherapy/chemotherapy and 26 % had no active treatment.
There are disparities in NSCLC surgical treatment and mortality for Aboriginal people compared with non-Aboriginal people in NSW. It is imperative that Aboriginal people are offered active lung cancer treatment, particularly those who are younger and without comorbidities and are therefore most likely to benefit, and are provided with assistance to access it if required.
Lung cancer is the most common cause of cancer death for both the Australian Aboriginal and non-Aboriginal populations . In New South Wales (NSW) the 5-year lung cancer-specific survival for Aboriginal people has been reported to be approximately half that of non-Aboriginal people . The reasons for this difference in survival are complex and have not yet been explored in NSW, although a study from Queensland , another state in Australia, attributed most of the difference to disparities in the medical treatment received by Aboriginal and non-Aboriginal people. This study found that, after adjusting for a range of disease and patient characteristics, the probability of Aboriginal people receiving active treatment at any stage of the illness was 35 % lower than for non-Aboriginal people . Similarly, a Western Australian study  found that the adjusted odds of receiving surgical treatment were 37 % lower for Aboriginal people than non-Aboriginal people diagnosed with lung cancer.
Surgical resection is the most effective treatment for non-metastatic non-small cell lung cancer (NSCLC), as well as for highly selected cases with a single site of metastases [5, 6]. However, the feasibility of surgery depends on the extent and location of the disease, and the ability of the patient to tolerate the procedure . When surgical resection is not indicated for NSCLC, radiotherapy, chemotherapy and/or palliative management are recommended . The optimal mix of treatments is determined by disease and patient characteristics, including spread of disease, comorbidities and age . It is possible that differences in these factors, as well as barriers to treatment access, lead to differences in the treatment of, and mortality from, lung cancer for Aboriginal and non-Aboriginal people.
To date, no studies of NSCLC treatment for Aboriginal people have been conducted in NSW, which is the most populous state in Australia (approximately 7 million people) and has an estimated 29 % of the total Australian Aboriginal population of approximately 148,000 people . Aboriginal people comprise approximately 2 % of the NSW population and, nationally, have a median age of 21 years compared with a median age for non-Aboriginal people of 37 years . Compared with Queensland and Western Australia, Aboriginal people in NSW are much more likely to live in major cities and inner regional areas , and therefore may have better access to specialist lung cancer treatment centres.
We use the descriptor ‘Aboriginal people’ throughout this paper to refer to the original people of Australia and their descendants, as endorsed by the Aboriginal Health and Medical Research Council in NSW and NSW Health .
The aim of this study was to compare surgical treatment for NSW Aboriginal and non-Aboriginal people diagnosed with non-metastatic NSCLC, and to examine the degree to which differences in patient and disease characteristics are associated with any disparities found. An additional objective was to describe radiotherapy and chemotherapy treatment for Aboriginal people diagnosed with NSCLC in NSW. Finally, we compared Aboriginal and non-Aboriginal people’s risk of death from NSCLC.
The methods used here have been described previously [10–12], and, briefly, involve the analysis of two different linked datasets. The first dataset (“NSW population data”) contained 21,127 incident lung cancer cases for 2001–2007 from the NSW Central Cancer Registry (CCR), linked to hospital episode records and death records. The second dataset (“Patterns of Care data”) comprised data from a medical records audit linked to CCR, hospital and death records. Eligible cases were aged 18 years and over, diagnosed with primary lung cancer (ICD-O-3 codes “C33” and “C34” and morphology codes ending in/3), and resident in NSW at diagnosis. The probabilistic linkage of records in the different datasets was carried out by the Centre for Health Record Linkage (CHeReL) using ChoiceMaker software and privacy-preserving methods (ChoiceMaker Technologies Inc., New York, US). The CHeReL reports approximately 0.1 % false positive and less than 0.1 % false negative linkages.
NSW population data
All invasive cancers diagnosed in NSW have been required by statute to be notified to the NSW Central Cancer Registry (CCR) since 1972. All inpatient episodes in all public and private hospitals in NSW are documented in and available from the NSW Ministry of Health’s Admitted Patient Data Collection (APDC).
As the focus of this study was comparing treatment after diagnosis, we excluded from the analysis 567 people (2.7 %) who were notified to the CCR by death certificate or after autopsy only. The remaining 20,560 people were linked to the APDC for the period 1 July 2000 to 30 June 2009. Death records including Aboriginal status up to 31 December 2007 were obtained from the Australian Bureau of Statistics (ABS). After excluding people with no matching APDC record (406, 1.9 %) as their Aboriginal status was unknown and they may have been treated in hospitals outside NSW  20,154 people were included in the analysis (Fig. 1).
In this analysis, a person was determined to be Aboriginal if they were listed as Aboriginal and/or Torres Strait Islander in any of their matching APDC or ABS records. We have not reported data separately for Torres Strait Islander people as there were very few identified in the source datasets.
Lung cancers were grouped by histological type as NSCLC, small cell lung cancer (SCLC) and “other and unspecified”, similar to the groupings used by the Australian Institute of Health and Welfare . NSCLC included squamous cell carcinoma, adenocarcinoma, large cell carcinoma and the group defined by the Australian Institute of Health and Welfare as “other specified carcinoma”.
Surgical treatment for localised and regional (“non-metastatic”) NSCLC was identified from the procedure codes listed in the APDC. Surgical treatment was defined as pneumonectomy, lobectomy, lung resection or resection of endotracheal tumour. Pleurodesis was not included as the main intent of this procedure is palliative. We restricted our analysis to surgical treatment because radiotherapy and chemotherapy, largely administered in outpatient services, are not routinely recorded in the APDC .
Age at diagnosis, sex, local government area (LGA) of residence at time of diagnosis, month and year of diagnosis, spread of disease at diagnosis and histology were obtained from the CCR. Spread of disease at diagnosis was reported by the CCR in four categories: localised (the tumour was contained within the organ in which it originated), regional (the tumour had spread to surrounding organs, adjacent tissue and/or nearby lymph nodes), distant (metastatic disease) and unknown . We could not assess differences between Aboriginal and non-Aboriginal people in the use of Positron Emission Tomography (PET) for cancer staging as we only had inpatient records and PET scans can be done on an outpatient basis.
Each person was allocated to one of three categories of geographic remoteness using the ARIA+ (Accessibility/Remoteness Index for Australia)  value for their LGA of residence. The ARIA+ index is calculated using road distances of a LGA to the nearest population centres or ‘service centres’. The service centres are categorised into major cities, inner regional and rural (which included outer regional, remote and very remote) based on population size. Quintiles of socioeconomic disadvantage were obtained by mapping their LGA of residence to the ABS Socio-Economic Indexes for Areas (SEIFA) Index of Relative Socio-Economic Advantage and Disadvantage [17, 18].
Information about comorbidities was obtained from the APDC diagnosis codes, which include the primary reason for hospitalisation and additional comorbidities . The presence of non-cancer comorbidities included in the Charlson Comorbidity Index  was obtained from hospital admission records from 12 months prior to diagnosis to 6 months after diagnosis. Those people who were not admitted to a NSW hospital during this 18 month period were excluded from analyses of factors related to receiving treatment (Fig. 1).
Smoking status was obtained from the APDC diagnosis codes. There is no code for non-smokers and it is not mandatory to record smoking status in the APDC. “Current smokers” were those who had a record of being a current smoker after diagnosis. “Former smokers” were those whose last smoking-related diagnosis prior to their cancer diagnosis was former smoker. “Ever smokers” were people with a record of current and/or former smoking, but it was not possible to determine if they were current smokers when they were diagnosed with cancer. “Never smokers” were defined as those who did not have any diagnosis of current or former smoker and were admitted at least once to a NSW hospital that was considered to record smoking status reliably, specifically at least 20 % of admissions had a smoking-related record. For the remainder, smoking status was coded as unknown.
Patterns of Care (POC) data
The Patterns of Care data were obtained through a medical records audit of a sample of Aboriginal people resident in NSW diagnosed with any invasive cancer in 2000–2011. Data were collected from 23 public hospitals and three Clinical Cancer Registries in NSW. The hospitals and registries were chosen based on size, recording of Aboriginal status, ability to extract electronic patient lists and the availability of a local Principal Investigator. Field officers confirmed Aboriginal status and extracted diagnosis and treatment information from paper and electronic medical records. In total, data were collected for 1304 Aboriginal people, of whom 219 were diagnosed with lung cancer in 2000–2010.
We collected disease and treatment information using a form largely based on a form developed for a previous study . The data collection form used in this study was reviewed by three oncologists to ensure that it covered all current forms of treatment. Data on disease characteristics included topography, histology, lymph node involvement and evidence of distant metastases. Spread of disease was categorized into three groups: non-metastatic, metastatic and unknown. Information on surgery, radiotherapy and chemotherapy included the timing of treatment, the intent of treatment (curative or palliative), and reasons for no treatment. Stereotactic radiotherapy became available in NSW after 2010 and so was not part of the standard treatment for NSCLC during the study period.
Records in the POC data were linked to the APDC for July 2000 to June 2009, the NSW Registry of Births, Deaths and Marriages death records for January 2000 to June 2010, and the CCR for 2000 to 2008 by the CHeReL. Histological type, place of residence, socioeconomic disadvantage and comorbidities were assigned in the same way as for the NSW population data. When information about treatment was missing in the POC data, but present in the APDC, details from the APDC were used to supplement the POC data.
Differences between Aboriginal and non-Aboriginal people with lung cancer were tested using Pearson’s chi-squared test. Tests of differences between Aboriginal people in the NSW population data and the POC data were not conducted, due to the overlap in the two datasets.
Logistic regression models were used to compare the odds of having surgical treatment for non-metastatic NSCLC for Aboriginal and non-Aboriginal people in the NSW population data. All models included Aboriginal status as an explanatory variable and the full model also contained: sex, age group, spread of disease at diagnosis, year of diagnosis, comorbidities, socioeconomic disadvantage quintiles and place of residence. Finally, smoking status was added to this model to investigate the additional effect on the odds of surgical treatment for Aboriginal compared to non-Aboriginal people.
Differences in the relationship between Aboriginal status and surgery across strata defined by the other covariates were tested by adding interaction terms to the full logistic regression model, with some strata collapsed, as shown in Table 3 . The difference in the time from diagnosis to surgery for those who had surgery was tested using the Mann–Whitney test.
The risk of death from NSCLC was analysed using competing risks regression [23, 24]. Follow-up was censored at 31 December 2008 for all surviving people, with non-lung cancer deaths treated as the competing risk. The main factor of interest was Aboriginal status. Sex, age group, spread of disease at diagnosis, year of diagnosis, surgical treatment, comorbidities, socioeconomic disadvantage quintiles, place of residence and smoking status were also included in the full regression model. We obtained the sub-distribution hazard ratios (SHRs) for each factor in the full model.
All analyses were performed using SAS software (release 9.3; SAS Institute Inc, Cary, North Carolina), R 3.1.0  and Stata/IC 13.1 (StataCorp).
The study using the NSW population data and the linkage of the Patterns of Care data to NSW health datasets were approved by the NSW Population and Health Services Research Ethics Committee and the Human Research Ethics Committee of the Aboriginal Health and Medical Research Council. Data collection for the Patterns of Care study was approved by the ethics committees of Royal Prince Alfred Hospital and the Aboriginal Health and Medical Research Council. Local Regional Governance Offices granted Site Specific Approval for data collection in participating hospitals and Clinical Cancer Registries. Seeking individual patient consent was determined to be impracticable by the lead ethics committees given the nature of the disease and the retrospective study methods that have been used.
NSW population data
Of the 20,154 people with lung cancer diagnosed in NSW in 2001–2007, 341 (1.7 %) were identified as Aboriginal (Table 1). Compared to the non-Aboriginal people, larger proportions of Aboriginal people were female (44 % versus 37 %) or under the age of 60 years at diagnosis (35 % versus 18 %) (Table 1). Aboriginal people were more likely to live outside major cities and in more socioeconomically disadvantaged areas, and were also more likely to be smoking around the time of diagnosis, and have comorbid diabetes or chronic pulmonary disease. Spread of disease at diagnosis was similar for Aboriginal and non-Aboriginal people. SCLC was more common for Aboriginal people, but the difference was not statistically significant.
Surgical treatment for non-metastatic NSCLC
When we restricted the analysis to people diagnosed with non-metastatic NSCLC, 30.8 % of the 120 Aboriginal people received surgery, compared with 39.5 % of non-Aboriginal people. The median time between diagnosis and surgery was similar for Aboriginal and non-Aboriginal people with non-metastatic NSCLC (24 days for Aboriginal and 20 days for non-Aboriginal people, p = 0.86). The types of surgical treatment received were similar, with 57 % of Aboriginal people and 58 % of non-Aboriginal people having lobectomies. The age-adjusted odds of having surgery were 46 % lower for Aboriginal than non-Aboriginal people (OR 0.54, 95 % CI 0.36–0.80). After also adjusting for sex, year of diagnosis, spread of disease, place of residence, comorbidities and socioeconomic disadvantage, the difference was reduced (OR 0.70, 95 % CI 0.46–1.05) and no longer statistically significant (Table 2). The proportions who were never smokers in Aboriginal and non-Aboriginal people were 10 % and 18 % respectively (Table 1). The addition of smoking status had little effect on the odds ratio for surgery for Aboriginal compared with non-Aboriginal people (OR 0.68, 95 % CI 0.46–1.03).
Overall in NSW, women, younger people, those with localised spread of disease, those living in major cities and areas with less socioeconomic disadvantage, and those without cardiovascular disease, renal disease or other comorbidities were more likely to receive surgery for their non-metastatic NSCLC (Table 2). The interaction between Aboriginal status and comorbidities was statistically significant (p = 0.018), with Aboriginal people with no comorbidities being approximately half as likely to have surgery as similar non-Aboriginal people (22 % versus 43 %), while there was no difference in proportions for those with at least one comorbidity (35 % versus 36 %) (Table 3). While this was the only statistically significant interaction, the proportions of Aboriginal people having surgery were consistently similar or lower compared to non-Aboriginal people across all categories of all covariates. For example, 51 % of non-Aboriginal people under the age of 60 years had surgery, compared to 37 % of older non-Aboriginal people. By contrast, for Aboriginal people the proportions having surgery were similar in both age groups (33 % for those under the age of 60 years and 30 % for older people).
Risk of death from NSCLC
The observed risk of death from NSCLC 5 years after diagnosis was higher for 266 Aboriginal people (83.3 % 95 % CI 77.5–87.7) than for 15,491 non-Aboriginal people (77.6 % 95 % CI 76.9–78.3) (Fig. 2). After adjusting for differences in sex, age at diagnosis, year of diagnosis, spread of disease, place of residence, comorbidities, socioeconomic disadvantage, smoking status and surgical treatment, Aboriginal people with NSCLC had a greater risk of death 5 years after diagnosis compared to non-Aboriginal people (Adjusted SHR 1.32 95 % CI 1.14–1.52). Sex, age at diagnosis, year of diagnosis, spread of disease at diagnosis, having surgical treatment, chronic pulmonary disease, other comorbid conditions, and socioeconomic disadvantage were also significantly associated with the increased risk of death from NSCLC for NSW people (Table 4).
Patterns of care data
Medical records for a sample of 219 Aboriginal people with lung cancer were reviewed. Records were extracted after death for 172 people. For the remaining 47 people, follow up was between 5 and 81 months, with a median follow up of 17 months. Of the 219 people in the sample, 174 had NSCLC, although four of these had incomplete treatment information.
While we could not make formal statistical comparisons, the characteristics of the Aboriginal people in the POC data were similar to those in the NSW population data, except that those in the POC data were slightly younger, less likely to have unknown spread of disease at diagnosis and were slightly more likely to live in a major city than the Aboriginal people in the NSW population data (Table 1).
Treatment received for NSCLC
Potentially curative treatment was received by half (47/94) of people with non-metastatic NSCLC and for 34/47 (72 %) of these the primary treatment was surgery. By contrast, only 2/71 (3 %) people with metastatic NSCLC received potentially curative treatment, while 51/71 (72 %) received palliative radiotherapy/chemotherapy. Of the 21 people with non-metastatic NSCLC who did not have treatment, eight died within 30 days of diagnosis. Of the remaining 13, the reasons for not being treated were: had comorbidities or they were considered too old to gain any benefit (6); patient choice (2); the tumour was unresectable (3); and no reason provided (2) (Table 5).
NSW population data
For Aboriginal people in NSW with non-metastatic NSCLC, the adjusted odds of having surgical treatment were 30 % lower compared with non-Aboriginal people. This finding was broadly similar to the findings from a Queensland study, where the probability of surgery for Aboriginal people compared to non-Aboriginal people, matched on age, sex and place of residence, was 61 % lower  and in Western Australia (where the odds were 37 % lower) . However these studies included all cases of lung cancer, not just non-small cell lung cancer. NSW Aboriginal people also had a higher risk of death from their non-metastatic NSCLC compared with non-Aboriginal people after adjusting for differences in sex, age at diagnosis, year of diagnosis, spread of disease, place of residence, comorbidities, socioeconomic disadvantage, smoking status and surgical treatment.
In NSW, non-Aboriginal people with non-metastatic NSCLC who were younger at diagnosis, without comorbidities or living in major cities were more likely to have surgical treatment. However, this was not true for Aboriginal people. Younger Aboriginal people had only slightly higher rates of surgery than older Aboriginal people, and Aboriginal people living in major cities had similar rates of surgery as those living in inner regional and rural areas, despite their geographical proximity to major hospitals and specialists. Counter-intuitively, Aboriginal people with comorbidities had a higher rate of surgery than those without comorbidities. The opposite was true for non-Aboriginal people. This last result is similar to that found in the Northern Territory , where the authors suggested that this may be due to lung cancer being incidentally detected in people under medical surveillance for other lung conditions. However, given the small number of Aboriginal people in our study with non-metastatic NSCLC, and the lack of information on long term comorbidities, no firm conclusions can be drawn. Most healthcare in Australia is paid for by Medicare, a government run universal health care system, through supply of care without charge in public hospitals and subsidised medical services and pharmaceuticals. Some services may require a co-payment when the fee charged is in excess of the subsidy and additional costs such as transport to services, parking and accommodation (except in hospital) are not reimbursed by Medicare. In addition, many private hospitals provide the infrastructure needed for cancer care and private health insurance is available to cover at least a part of the cost of private hospital care. By arrangement in some regional areas private cancer services provide care for public patients free of charge when no public services are available. Specialised cancer services in NSW are largely located in major cities or inner regional areas. Therefore the lower proportion with private health insurance amongst Aboriginal people  may have also contributed to the lower surgical treatment rate, as it has been previously reported  that NSW residents with private health insurance (or with coverage by the Department of Veterans’ Affairs) with localised NSCLC had twice the odds of receiving a resection compared to people who were uninsured.
The observed increased risk of death from NSCLC for Aboriginal people compared to non-Aboriginal people is similar to the patterns we have previously reported for women with breast cancer  and for men with prostate cancer in NSW , and also similar to results others have reported for lung cancer in Queensland  and the Northern Territory  and NSW . Similar increased risks have been shown for Maoris in New Zealand , and Canadian First Nations  and Inuit  peoples.
A limitation of the NSW population data is potential misclassification of Aboriginal and non-Aboriginal people in the APDC. However, an audit in 2007–08 found that all 2661 non-Aboriginal patients interviewed were correctly classified as non-Aboriginal in the APDC , suggesting that such misclassification is rare. In the same audit, 93 % of people who identified as Aboriginal at interview were recorded as Aboriginal in the APDC . The proportion of Aboriginal people misclassified in our study is likely to be even lower, as we used any recording of Aboriginal status in any linked records to assign a person’s Aboriginal status. If the Aboriginal people who were misclassified received more (or less) treatment than the Aboriginal people who were correctly classified, our results could be biased away from (or to) the null hypothesis of similar patterns of care.
Major strengths of this study are that it was population-based and the first study of treatment of lung cancer for Aboriginal people in NSW. NSW has the largest Aboriginal population and, compared with Queensland and Western Australia, where the two previous studies were conducted, a greater proportion of NSW Aboriginal people lived in areas close to the major hospitals where lung cancer treatment is predominantly provided.
Patterns of care data
One half of Aboriginal people with non-metastatic NSCLC in the Patterns of Care data received potentially curative treatment in the first 12 months after diagnosis, 28 % had palliative radiotherapy and/or chemotherapy only, and 22 % had no treatment.
Limitations of the Patterns of Care data include the non-random sampling of hospitals from which medical records were extracted, and the exclusion of people who did not attend a hospital following their lung cancer diagnosis. As a result, the participants may not be representative of all Aboriginal people with lung cancer diagnosed in 2000–2010. However, the demographic and disease characteristics of the Aboriginal people in the POC data and the NSW population data were broadly similar, suggesting that the cases in the POC data may indeed be a good representation of Aboriginal people with lung cancer in NSW. Also, because only people who attended hospital after a lung cancer diagnosis were included in the POC data, the proportions who received treatment may be overestimated. However, this bias may be relatively small as the proportion of Aboriginal people with non-metastatic NSCLC receiving surgery was similar in the NSW population data and the POC data (31 % and 36 %).
Cultural, logistical and socio-economic barriers might explain some of this lack of optimal care. For example limited access to transport or childcare may restrict the ability to undergo treatment . Aboriginal people in NSW have been shown to have a lower health literacy in relation to cancer  and can perceive a lack of social inclusion  with healthcare systems and these may be barriers to them receiving optimal care. Thompson et al.  proposed a number of recommendations to increase the access to new cancer services for Aboriginal people including considering public transport and parking facilities, allowing room for families to visit and/or attend appointments and providing childcare facilities. The same authors , as well as Davidson et al.  in a review, also suggested that addressing cultural needs and beliefs as well as reducing upfront medical, transport and parking costs for Aboriginal people is likely to improve their access to existing cancer services.
There is a disparity in the surgical treatment of NSCLC between Aboriginal and non-Aboriginal people in NSW. Counter-intuitively this is particularly true for Aboriginal people who were younger, lived in major cities and inner regional areas, or those without comorbidities. However, a reasonable proportion of Aboriginal people received radiotherapy and chemotherapy. It is therefore possible that the disparity in surgical treatment received, particularly for those diagnosed before 60 years of age, those without comorbidities, or those living in urban areas, is the major contributor to the increased risk of death from lung cancer for Aboriginal people. Consequently it is imperative that Aboriginal lung cancer patients who are most likely to benefit from active treatment are offered such treatment, and are provided with assistance to access it if required.
Availability of data and materials
Data analysed for this paper are not able to be shared on any publicly available repository due to NSW privacy laws. Approvals would be required from the lead ethics committee as well as the data custodians, before any further data could be provided.
Australian Bureau of Statistics. Causes of Death 2008. Canberra: Australian Bureau of Statistics; 2010.
Cancer Institute NSW. Cancer in NSW Aboriginal Peoples: Incidence, Mortality and Survival. Sydney: Cancer Institute NSW; 2012.
Coory M, Green A, Stirling J, Valery P. Survival of Indigenous and non-Indigenous Queenslanders after a diagnosis of lung cancer: a matched cohort study. Med J Aust. 2008;188:562–6.
Hall SE, Holman CD, Sheiner H. The influence of socio-economic and locational disadvantage on patterns of surgical care for lung cancer in Western Australia 1982–2001. Aust Health Rev. 2004;27:68–79.
Cancer Council Australia Lung Cancer Guidelines Working Party. Clinical practice guidelines for the treatment of lung cancer. http://wiki.cancer.org.au/australia/Guidelines:Lung_cancer. Accessed 22 April 2016.
Cancer Council Australia. Clinical Practice Guidelines for the Prevention, Diagnosis and Management of Lung Cancer. Sydney: National Health and Medical Research Council; 2004.
Quint LE. Lung cancer: assessing resectability. Cancer Imaging. 2004;4:15–8.
Australian Bureau of Statistics. Population Characteristics, Aboriginal and Torres Strait Islander Australians, Australia 2006. Canberra: Australian Bureau of Statistics; 2010.
NSW Department of Health. Communicating positively: A guide to appropriate Aboriginal terminology. Sydney: NSW Health; 2004.
Supramaniam R, Gibberd A, Dillon A, Goldsbury DE, O Connell DL. Increasing rates of surgical treatment and preventing comorbidities may increase breast cancer survival for Aboriginal women. BMC Cancer. 2014;14:163.
Rodger JC, Supramaniam R, Gibberd AJ, Smith DP, Armstrong BK, Dillon A, O'Connell DL. Prostate cancer mortality outcomes and patterns of primary treatment for Aboriginal men in New South Wales, Australia. BJU Int. 2015;115 Suppl 5:16–23.
Gibberd A, Supramaniam R, Dillon A, Armstrong BK, O’Connell DL. Are Aboriginal people more likely to be diagnosed with more advanced cancer? Med J Aust. 2015;202:195–9.
Goldsbury DE, Armstrong K, Simonella L, Armstrong BK, O’Connell DL. Using administrative health data to describe colorectal and lung cancer care in New South Wales, Australia: a validation study. BMC Health Serv Res. 2012;12:387.
Australian Institute of Health and Welfare and Cancer Australia. Lung cancer in Australia: an overview. Canberra: Australian Institute of Health and Welfare; 2011.
Cancer Institute NSW. Cancer in NSW Aboriginal peoples: completeness and quality of Aboriginal status data on the NSW Central Cancer Registry. http://www.cancerinstitute.org.au/publications/cancer-in-nsw-aboriginal-peoples-completeness-and-quality-of-aboriginalstatus-data-on-the-nsw-central-cancer-registry. Accessed 22 April 2016.
Department of Health and Aged Care. Measuring Remoteness: Accessibility/Remoteness Index of Australia (ARIA). Canberra: Department of Health and Aged Care; 2001.
Australian Bureau of Statistics: Census of Population and Housing. Socio-Economic Indexes for Areas (SEIFA), Australia - Data Cube only, 2001. Canberra: Australian Bureau of Statistics; 2006.
Australian Bureau of Statistics. Census of Population and Housing: Socio-Economic Indexes for Areas (SEIFA), Australia - Data Cube only, 2006. Canberra: Australian Bureau of Statistics; 2006.
Population and Public Health Division. New South Wales Admitted Patient Report 2012. Sydney: NSW Ministry of Health; 2012.
Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40:373–83.
Vinod SK, O'Connell DL, Simonella L, Delaney GP, Boyer M, Peters M, et al. Gaps in optimal care for lung cancer. J Thorac Oncol. 2008;3:871–9.
Tarone RE. On heterogeneity tests based on efficient scores. Biometrika. 1985;72:91–5.
Gray RJ. A class of K-sample tests for comparing the cumulative incidence of a competing risk. Ann Stat. 1988;16:1141–54.
Fine JP, Gray RJ. A Proportional Hazards Model for the Subdistribution of a Competing Risk. J Am Stat Assoc. 1999;94:496–509.
R Development Core Team. R:A Language and Environment for Statistical Computing. Vienna: R Foundation for Statistical Computing; 2012. http://www.R-project.org/. Accessed 22 April 2016.
Condon JR, Barnes T, Armstrong BK, Selva-Nayagam S, Elwood JM. Stage at diagnosis and cancer survival for Indigenous Australians in the Northern Territory. Med J Aust. 2005;182:277–80.
Lowenthal RM, Grogan PB, Kerrins ET. Reducing the impact of cancer in Indigenous communities: ways forward. Med J Aust. 2005;182:105–6.
Currow DC, You H, Aranda S, McCaughan BC, Morrell S, Baker DF, et al. What factors are predictive of surgical resection and survival from localised non-small cell lung cancer? Med J Aust. 2014;201:475–80.
Haynes R, Pearce J, Barnett R. Cancer survival in New Zealand: ethnic, social and geographical inequalities. Soc Sci Med. 2008;67:928–37.
Nishri ED, Sheppard AJ, Withrow DR, Marrett LD. Cancer survival among First Nations people of Ontario, Canada (1968–2007). Int J Cancer. 2015;136:639–45.
Louchini R, Beaupré M. Cancer incidence and mortality among Aboriginal people living on reserves and northern villages in Quebec, 1988–2004. Int J Circumpolar Health. 2008;67:445–51.
Australian Institute of Health and Welfare. Indigenous identification in hospital separations data - quality report. Canberra: Australian Institute of Health and Welfare; 2010.
Thompson SC, Shahid S, Bessarab D, Durey A, Davidson PM. Not just bricks and mortar: planning hospital cancer services for Aboriginal people. BMC Res Notes. 2011;4:62.
Treloar C, Gray R, Brener L, Jackson C, Saunders V, Johnson P, et al. Health literacy in relation to cancer: Addressing the silence about and absence of cancer discussion among Aboriginal people, communities and health services. Heal Soc Care Community. 2013;21:655–64.
Treloar C, Gray R, Brener L, Jackson C, Saunders V, Johnson P, Harris M, Butow P, Newman C. “I can’t do this, it's too much”: building social inclusion in cancer diagnosis and treatment experiences of Aboriginal people, their carers and health workers. Int J Public Health. 2014;59:373–9.
Thompson SC, Shahid S, Greville HS, Bessarab D. “A whispered sort of stuff” A community report on research around Aboriginal people’s beliefs about cancer and experiences of cancer care in Western Australia. Perth: Cancer Council Western Australia; 2011.
Davidson PM, Jiwa M, Digiacomo ML, McGrath SJ, Newton PJ, Durey AJ, et al. The experience of lung cancer in Aboriginal and Torres Strait Islander peoples and what it means for policy, service planning and delivery. Aust Health Rev. 2013;37:70–8.
The Authors would like to acknowledge the Chief Investigators of the Aboriginal Patterns of Cancer Care Project (APOCC), the APOCC Aboriginal Advisory Group and Ethics Committee of The Aboriginal Health and Medical Research Council for providing advice on the content of this paper. We would also like to thank Veronica Saunders, the APOCC Community Liaison Officer for her cultural guidance on the APOCC project and John Dennis and Kristie Weir who collected data for the Patterns of Care Study. We would also like to acknowledge Clare Kahn for proofreading drafts of the paper.
The authors declare that they have no competing interests.
All authors listed in this paper fulfil the criteria for authorship, and there is no one else who fulfils these criteria who is not listed here as an author. Contributions were as follows: AG conducted data analysis and contributed to the interpretation and wrote the original drafts of the paper; RS contributed to study design, data analysis and interpretation, and to all drafts of the paper; AD and BKA contributed to study design, interpretation and to final drafts of the paper; DO’C contributed to study design, data interpretation and all drafts of the paper. All authors read and approved the final manuscript.
About this article
Cite this article
Gibberd, A., Supramaniam, R., Dillon, A. et al. Lung cancer treatment and mortality for Aboriginal people in New South Wales, Australia: results from a population-based record linkage study and medical record audit. BMC Cancer 16, 289 (2016). https://doi.org/10.1186/s12885-016-2322-1
- Lung cancer
- Patterns of care
- Aboriginal people
- Cancer survival